Participated · Series B · Dec 2021

AnHeart Therapeutics is a clinical-stage global biopharmaceutical group developing next-generation precision oncology therapeutics, operating from offices in the US and China and registered in the Cayman Islands as AnBio Therapeutics Ltd. Its lead asset, taletrectinib, is a potent, highly selective next-generation ROS1/NTRK inhibitor in Phase 2 trials for first- and second-line ROS1 fusion–positive NSCLC and in an NTRK fusion–positive solid tumor basket trial; it is reported to cross the blood–brain barrier and overcome crizotinib resistance. Taletrectinib is being studied in the China TRUST trial (NCT04395677), the global TRUST II trial (NCT04919811), and the NTRK basket trial (NCT04617054), and interim TRUST Phase 2 data for NSCLC have been published at ASCO and CSCO. The company’s pipeline also includes AB-218, an mIDH1 inhibitor in Phase 2 for lower grade glioma, cholangiocarcinoma, AML and other tumors, and AB-329, an AXL inhibitor in Phase 1 intended for use in combination with checkpoint inhibitors or chemotherapies. The company plans to use recent proceeds to advance taletrectinib’s clinical development and to support continued expansion of its precision oncology pipeline and team. Since its founding in December 2018, AnHeart has raised $100 million in gross proceeds from private financings. AnHeart Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, headquartered in Hangzhou with offices in Beijing, Shanghai and New York. Its lead candidate, taletrectinib, is a next-generation, potent and highly selective ROS1/NTRK inhibitor that can cross the blood–brain barrier and was licensed from Daiichi Sankyo. Two Phase 1 studies in the U.S. and Japan reported promising safety and efficacy, with mPFS of 24.9 months in TKI‑naïve patients and 18.4 months in 1 TKI‑pretreated patients (data cutoff March 2019). Taletrectinib inhibits both ROS1 fusion wild type and crizotinib-resistant secondary mutations, including G2032R, and is being advanced into global Phase 2 trials. The company plans to use proceeds from its recent financing to execute the global development plan for taletrectinib and to expand and deepen its oncology portfolio over time. AnHeart was formed in November 2018 and is managed by industry veterans and financially backed by venture capital funds.

Participated · Series B · Oct 2021

Structure Therapeutics, formerly ShouTi, is a clinical-stage global biopharmaceutical company that leverages structural biology and computational design to discover next-generation small-molecule therapies focused on GPCR targets. Its lead program, GSBR-1290, is an orally available small-molecule GLP‑1 receptor agonist being developed for type 2 diabetes mellitus and obesity. The company completed dosing in a single ascending dose Phase 1 study of GSBR-1290 in 48 healthy volunteers to evaluate safety, tolerability and pharmacokinetics; no serious adverse events were reported. Structure Therapeutics designs biased GLP‑1R agonists intended to mitigate β‑arrestin–mediated internalization and desensitization and to offer a differentiated oral alternative to peptide biologics. Proceeds from the recent financing will be used to advance the lead programs through clinical investigation and to expand application of its structure-based drug discovery platform across GPCR targets. The company announced a corporate name change to Structure Therapeutics to reflect its foundation in structural biology and computational design. ShouTi combines state-of-the-art computational chemistry, structural biology, and large-scale data integration to design orally available medicines with improved pharmaceutical properties. The platform focuses on high-resolution membrane protein structures, particularly GPCRs, to convert biologics and peptide therapeutics into small molecules with enhanced bioavailability and stability. ShouTi is advancing a clinical-stage pipeline targeting chronic cardiovascular, metabolic, and pulmonary diseases. Proceeds from its recent financing will be used to advance the discovery platform and continue development of the clinical-stage programs. The leadership team includes experienced drug developers and pioneers in high-throughput structure-based drug discovery, led by CEO Raymond Stevens. With the Series B, ShouTi has raised $158 million since initiating operations.

Participated · Equity · Aug 2021

Visus Therapeutics is a clinical-stage pharmaceutical company based in Seattle, WA and Orange County, CA focused on developing innovative ophthalmic therapies. Its lead asset, BRIMOCHOL, is an investigational once-daily eye drop for presbyopia that combines two FDA‑approved drugs, carbachol and brimonidine. BRIMOCHOL has been studied in more than 200 patients across six clinical studies. Topline data from a Phase 2 study were expected in the second half of 2021 and, pending affirmative results, the company planned to immediately initiate pivotal Phase 3 studies. The company intends to use the new funds to advance clinical and commercial efforts for BRIMOCHOL and to support research and development of its early‑stage ophthalmic pipeline. Ben Bergo is co‑founder and CEO. Visus Therapeutics is a clinical-stage pharmaceutical company pursuing development of the world’s first presbyopia-correcting eye drop intended to last a minimum of eight hours. Its lead clinical candidate, BRIMOCHOL, is an investigational once-daily eye drop designed to correct the loss of near vision associated with presbyopia. The company operates offices in Seattle and Orange County, California, and is advancing a pipeline of early-stage ophthalmic product candidates. There are currently no FDA-approved medications for presbyopia, a condition that typically begins in the 40s and affects billions globally, including approximately 123 million adults in the U.S. Visus intends to use proceeds from its recent financing to advance the clinical development program for BRIMOCHOL.

Participated · Series C · Jun 2021

Insilico Medicine develops Pharma.AI, a generative AI platform that spans biology, generative chemistry, clinical medicine and research and integrates LLM-powered engines such as Nach01 and Dora. The company operates Life Star1, a fully robotic lab that includes a bipedal humanoid AI Scientist to automate and optimize research workflows. Insilico has built a wholly-owned discovery portfolio of 30 assets, with 10 assets having received IND clearance, and its lead candidate Rentosertib has completed a Phase IIa trial showing favorable safety and a dose-dependent FVC response. The company reports it can nominate preclinical candidates in 12–18 months and synthesize/test 60–200 molecules per program, reflecting accelerated early-stage discovery. Insilico also generates sustainable revenue through out-licensing agreements (collectively valued at over $2.1 billion) and collaborations (collected value over $1.4 billion), with milestone payments contributing to financial performance. Future plans announced include refining AI models and algorithms, expanding and updating its automated lab, advancing clinical validation of its flagship IPF candidate, and accelerating other in-house and co-developed pipelines. Insilico Medicine is a clinical-stage, end-to-end AI-driven drug discovery company led by founder and CEO Alex Zhavoronkov. The company develops AI platforms that connect biology, chemistry, and clinical-trials analysis using deep generative models, reinforcement learning, transformers, and other machine-learning techniques. Its platforms are used to discover novel targets and design molecular structures with desired properties across oncology, fibrosis, immunity, central nervous system, and aging-related diseases. Insilico says it will use the new funding to accelerate its internal programs and to apply its platform to uncover more novel therapeutics. The company recently announced promising preclinical candidates for COVID-19 (and related variants) and for ALS. Insilico is headquartered in Hong Kong and sources R&D and management resources across the USA, Belgium, Russia, the UK, Taiwan, and China. Insilico Medicine builds an AI-driven drug discovery platform that identifies new targets and molecules and also develops its own therapeutics across fibrosis, immunology, oncology and CNS. The company began as a discovery-focused business and, since 2019, has been advancing in-house drug programs, nominating eight preclinical candidates since 2021. It generates revenue from R&D collaborations (including upfronts and milestones) and customer subscriptions to its platform. Insilico is in the R&D stage, is not yet profitable, and employs about 200 people across six countries and regions. The firm plans to use new capital to fund Phase I studies, further develop its AI platform, and pursue global expansion and strategic initiatives such as a robotic drug discovery laboratory and a robotic biological data factory. A prototype robotic lab is planned for Suzhou and will include AGVs and a phenotyping partnership with X-Imaging. Insilico Medicine operates AI platforms (PandaOmics for target discovery and Chemistry42 for molecule design) to accelerate drug discovery and reduce guesswork in target-to-molecule development. The company demonstrated a proof-of-concept by identifying a novel target for idiopathic pulmonary fibrosis and designing a candidate that progressed through animal studies. That IPF project condensed preclinical development to about 18 months at a cost of roughly $2.6 million, and Insilico says it has 16 therapeutic assets across programs. The company is filing an investigational new drug (IND) application with the FDA, plans to begin human dosing this year, and aims to start a clinical trial late this year or early next year. Insilico has collaborated with Pfizer, Johnson & Johnson, Taisho Pharmaceuticals, and announced a new partnership with Teva to use PandaOmics. Insilico Medicine is a Hong Kong-based developer of next-generation AI for drug discovery that applies deep learning across the drug discovery and development process. Its core technologies include generative chemistry and target-identification platforms, and the company collaborates with biopharmaceutical firms using disease-relevant assays to validate solutions and generate machine-learnable data. Insilico has identified promising targets across cancer, fibrosis, NASH, immunology and CNS. The company completed a $37M Series B financing to support commercialization and pipeline advancement. It plans to use the funds to commercialize its validated generative chemistry and target-identification technology, build a senior management team with pharmaceutical experience, and further develop and partner on specific therapeutic programs.

Participated · Series C · Jul 2020

Harbour BioMed develops next-generation biologics—primarily fully human monoclonal antibodies—targeting cancer, immunologic diseases and COVID-19. The company builds its pipeline using two patented transgenic mouse platforms (Harbour Mice®), including HCAb and H2L2, and integrates technologies such as HBICE™ and the Beacon® Optofluidic System to accelerate discovery. HBM reports more than 30 programs and currently has five products in clinical development, including HBM9161 (anti-FcRn), HBM9036 (Tanfanercept) and HBM4003 (anti-CTLA4). It maintains collaborations with AbbVie, Utrecht University, Erasmus Medical Center and Mount Sinai to advance therapeutic and COVID-19 antibody programs. HBM has operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou and Shanghai, China. The company completed a $102.8M Series C (following a $75M Series B+ in March 2020) to support final development and initial commercialization of late-stage assets and to advance earlier-stage discovery programs. Harbour BioMed (HBM) is a clinical-stage biopharmaceutical company building a proprietary pipeline of next-generation biotherapeutics, including fully human heavy chain only antibodies (HCAb) and bispecifics. Its discovery platforms include patented Harbour Mice® transgenic mouse platforms and the HBICE™ immune cell engager technology, which the company also licenses. HBM is advancing multiple clinical-stage assets, including HBM4003 (anti-CTLA-4), HBM9161 (anti-FcRn), HBM9036 (dry eye disease) and HBM9167 (anti–PD-L1), and has collaborations such as with Mount Sinai Health System on COVID-19. The company has ongoing and planned international clinical studies, has received an IND approval from the FDA for HBM4003, and has reported recent progress toward mid-late stage trials and registration studies. HBM has operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou and Shanghai, China. The company completed an $85 million Series B in August 2018 and has now raised additional capital to accelerate its pipeline. Harbour BioMed centers its discovery and development efforts on two patented transgenic mouse platforms (Harbour Mice) to generate fully human therapeutic antibodies. The company builds a proprietary pipeline through internal discovery and by in‑licensing clinical‑stage assets, and it also licenses its platforms to companies and academic institutions via its Harbour Antibodies subsidiary. Its programs include an anti‑FcRn antibody for multiple autoimmune diseases and a biologic for inflammatory dry‑eye disease (developed for Greater China), a CD3‑based bispecific against HER2 (for Greater China), and a clinical‑stage anti‑PD‑L1 antibody being developed worldwide outside China. Harbour has expanded collaborations around its transgenic technologies and established preclinical and clinical development operations and an experienced team since its founding. Financially, the company has progressed from a December 2016 Series A (around $50M) and an A+ round in early 2018 to a newly completed Series B to support pipeline advancement. The company lists operations in Shanghai, Rotterdam (The Netherlands), and Cambridge, Mass. Harbour BioMed discovers and develops innovative therapeutics for cancer with a focus on immuno-oncology and immunological diseases. Its discovery platforms center on two patented transgenic "Harbour Mice" strains (H2L2 and HCAb) owned by Harbour Antibodies BV for human antibody discovery. The company builds a proprietary pipeline through internal discovery programs, in-licensing clinical-stage assets, and licensing its platforms to partners and academic institutions. Within its first year it acquired and integrated Harbour Antibodies BV and has since licensed in two clinical-stage biologics and assembled an experienced clinical development and regulatory science team. Management plans to submit at least two INDs in 2018 targeting multiple indications for Chinese patients. Harbour BioMed is headquartered with R&D centers in China and maintains a Business Operation and Innovation Center in Boston and an Antibody Technology Innovation Center in Rotterdam.